GlassScriptPhysician profile
Gregory Thomas Lagos
NPI 1316946825
$10,838.55
in general payments reported to CMS, 2019-2025
29 companies · $1,939 in 2025
The $1,939 reported for 2025 was more than what 75% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,676 · 2020: $771 · 2021: $1,213 · 2022: $1,661 · 2023: $1,535 · 2024: $2,044 · 2025: $1,939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,215 · Education: $303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,214.60 |
| Education | $302.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,919.05 | 2019-2025 | |
| Janssen Biotech, INC. | $2,157.65 | 2019-2025 | Tremfya, Simponi Aria |
| Amgen INC. | $831.71 | 2020-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $821.39 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Regeneron Healthcare Solutions, INC. | $606.99 | 2019-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $548.26 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $509.72 | 2019-2025 | Nemluvio |
| Novartis Pharmaceuticals Corporation | $446.44 | 2019-2025 | |
| Dermavant Sciences, INC. | $262.36 | 2022-2024 | Vtama |
| Celgene Corporation | $223.39 | 2019 | |
| Incyte Corporation | $194.27 | 2022-2025 | Opzelura |
| Pfizer INC. | $187.68 | 2019-2025 | |
| Organon LLC | $153.44 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.52 | 2022-2025 | Spevigo |
| Lilly USA, LLC | $123.93 | 2020-2024 | Taltz, Ebglyss |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $107.00 | 2021 | |
| Arcutis Biotherapeutics, INC. | $92.45 | 2023-2025 | Zoryve |
| Hill Dermaceuticals, INC. | $88.26 | 2025 | Tolak |
| Leo Pharma INC. | $77.84 | 2019-2022 | |
| Genzyme Corporation | $64.37 | 2022-2023 | |
| Dusa Pharmaceuticals, INC. | $57.23 | 2019 | |
| Ucb, INC. | $46.17 | 2023 | Bimzelx |
| Prugen, INC. Pharmaceuticals | $39.82 | 2019 | |
| Paratek Pharmaceuticals, INC. | $34.53 | 2023 | Nuzyra |
| Merck Sharp & Dohme LLC | $26.67 | 2019 | |
| Biofrontera INC. | $19.87 | 2019 | |
| Mission Pharmacal Company | $16.97 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $16.93 | 2024 | Arazlo |
| Nabriva Therapeutics, Plc | $16.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Lagos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.